<DOC>
	<DOCNO>NCT02376920</DOCNO>
	<brief_summary>Uveal Melanoma rare cancer approximately 3,000 case diagnose US every year . Nearly half experience spread cancer outside eye . The DecisionDx-UM gene expression test classify individual 's tumor low risk ( class 1 ) high risk ( class 2 ) spreading . This study do collect information physician use DecisionDx-UM result design individual treatment plan . It also track outcome uveal melanoma population receive DecisionDx-UM testing .</brief_summary>
	<brief_title>5 Year Registry Study Track Clinical Application DecisionDx-UM Assay Results Associated Patient Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients diagnosis Uveal Melanoma Patients whose physician deems appropriate DecisionDxUM test Patients reasonably able follow enrol physician regular interval assessment outcome data Patients form cancer</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>occular melanoma</keyword>
	<keyword>melanoma eye</keyword>
	<keyword>DecisionDx-UM</keyword>
</DOC>